Production (Stage)
Cognition Therapeutics, Inc.
CGTX
$0.3174
$0.01916.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.33% | -9.15% | 3.99% | -5.43% | -2.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.96% | 6.39% | 30.33% | 37.46% | 29.56% |
| Operating Income | 3.96% | -6.39% | -30.33% | -37.46% | -29.56% |
| Income Before Tax | -15.76% | -31.73% | -50.12% | -36.89% | -20.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.76% | -31.73% | -50.12% | -36.89% | -21.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.76% | -31.73% | -50.12% | -36.89% | -21.22% |
| EBIT | 3.96% | -6.39% | -30.33% | -37.46% | -29.56% |
| EBITDA | 3.98% | -6.38% | -30.36% | -37.50% | -29.58% |
| EPS Basic | 19.80% | -1.40% | -21.00% | -8.98% | 3.61% |
| Normalized Basic EPS | 19.31% | -1.91% | -21.00% | -8.97% | 4.20% |
| EPS Diluted | 18.95% | -1.84% | -21.36% | -8.67% | 4.11% |
| Normalized Diluted EPS | 19.31% | -1.91% | -21.00% | -8.97% | 4.20% |
| Average Basic Shares Outstanding | 49.90% | 32.30% | 25.66% | 24.90% | 23.24% |
| Average Diluted Shares Outstanding | 49.90% | 32.30% | 25.66% | 24.90% | 23.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |